nalinakshi

on the verge of correction

nalinakshi Updated   
NYSE:TDOC   Teladoc Health, Inc.
Teladoc (TDOC) is the perfect example of how this next-gen theme is already making an impact. The company was founded in 2002 with a goal of tackling healthcare’s three biggest issues: access, cost and quality. Today, it’s the leading provider of telehealth medical visits in the country. TDOC boasts being able to put you in contact with a licensed doctor in under 10 minutes — whether it’s via the phone, internet or mobile app.

The company already has more than 15 million users and a 95% satisfaction rate. Sure, it may not take off with older generations used to seeing their doctor in person, but the millennials, who are used to having everything they need at their fingertips, are more game for a remote visit. Remember, we’re looking at the areas that will drive the next generation of profits on Wall Street and this is definitely revolutionary technology.

Virtual doctors’ offices aren’t the only interesting thing going on within the theme, though. As the Baby Boomers age, the demand for new and better healthcare (everything from drugs to medical devices) is growing rapidly. And President Trump has already stated that he plans to speed up and simplify the FDA’s drug approval process. This is great news for all biotech companies, but specifically the smaller ones that Wall Street isn’t keeping as close of an eye on.

Then there’s the wearables space. More and more often I’m seeing people walk down the street with some sort of fitness tracker on their wrists. Whether it’s a Fitbit (FIT), Apple (AAPL) Watch or some other brand of tracker, there are all kinds of dynamic devices out there that allow users to monitor all their vital health stats. As new products come on the market, investors will have more options to profit from.

There’s no question the future is changing, and I suspect healthcare is going to look a lot different down the road thanks to the ever-growing tech space.
Comment:
around 23.5 forms the next good place to buy

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.